Frontier Medicines Announces Milestone Payment in AbbVie Partnership, Following Advancement of Lead Candidates Targeting a Historically Undruggable Transcription Factor

"By applying the Frontier™ Platform, our team was able to target a historically intractable transcription factor that has implications across oncology treatment," said Chris Varma, Ph.D., chairman, CEO, and co-founder of Frontier Medicines. "This progress validates our platform's ability to unlock undruggable targets for small molecule treatment and we look forward to further advances in our collaboration with AbbVie." About Frontier and AbbVie Partnership Frontier Medicines is a clinical stage precision me ...